News & Updates
Filter by Specialty:
Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
In patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC) who were ALK inhibitor-naïve, brigatinib showed superior efficacy and safety over crizotinib, according to the final results of the phase III ALTA-1L* trial presented at ELCC 2022.
Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
30 Apr 2022
Parathyroidectomy does not lessen morbidity, mortality in mild hyperparathyroidism
Parathyroidectomy (PTX) seems ineffective at reducing morbidity or mortality in patients with mild primary hyperparathyroidism (PHPT) relative to observation without intervention, suggests a study. For at least a decade, observation has seen no evidence of adverse effects regarding mortality, fractures, cancer, cardiovascular (CV) and cerebrovascular (CBV) events, or renal morbidities.
Parathyroidectomy does not lessen morbidity, mortality in mild hyperparathyroidism
29 Apr 2022
Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.
